Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Utomilumab

Generic Name: Utomilumab

Drug Type: Biotech

CAS Number: 1417318-27-4

Unique Ingredient Identifier: 6YY8O697VF

Overview

Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Background

Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3

Active, not recruiting

Posted: 2021/09/28

Sponsor:Pfizer

ID:NCT05059522

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Phase 2

Recruiting

Posted: 2019/06/03

Sponsor:

Laura Huppert, MD, B...

ID:NCT03971409

Rituximab + Immunotherapy in Follicular Lymphoma

Phase 1

Terminated

Posted: 2018/08/17

Sponsor:Dana-Farber Cancer I...

ID:NCT03636503

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Posted: 2018/02/22

Sponsor:

City of Hope Medical...

ID:NCT03440567

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 2

Active, not recruiting

Posted: 2018/01/30

Sponsor:

Adrienne G. Waks

ID:NCT03414658

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy